Comparison of baseline demographics and efficacy outcomes in patients with ND IDH1mut AML treated on the pivotal registrational trials of VIALE-A (pooled analysis) and AGILE
| Efficacy-evaluable population . | AZA with VEN N = 33 . | IVO with AZA N = 72 . |
|---|---|---|
| Age, median (range or IQR) | 76 (64-90) | 76 (58-84) |
| Response outcomes | ||
| Composite CR (CRc*) rate | 67% | 53% |
| CR rate | 27% | 47% |
| Duration of response (mo) | ||
| Median time to CRc (range) | 1.2 (0.8-8.1) | 4.0 (1.7-8.6) |
| Median duration of CRc (95% CI) | 21.9 (7.8-NE) | NE (13.0-NE) |
| Survival outcomes (mo or percentage) | ||
| Median OS (95% CI) | 15.2 (7.0-NE) | 24 (11.3-34.1) |
| Estimated 12-mo survival probability (95% CI) | 57.6% (39.1-72.3) | ~ 64% |
| Efficacy-evaluable population . | AZA with VEN N = 33 . | IVO with AZA N = 72 . |
|---|---|---|
| Age, median (range or IQR) | 76 (64-90) | 76 (58-84) |
| Response outcomes | ||
| Composite CR (CRc*) rate | 67% | 53% |
| CR rate | 27% | 47% |
| Duration of response (mo) | ||
| Median time to CRc (range) | 1.2 (0.8-8.1) | 4.0 (1.7-8.6) |
| Median duration of CRc (95% CI) | 21.9 (7.8-NE) | NE (13.0-NE) |
| Survival outcomes (mo or percentage) | ||
| Median OS (95% CI) | 15.2 (7.0-NE) | 24 (11.3-34.1) |
| Estimated 12-mo survival probability (95% CI) | 57.6% (39.1-72.3) | ~ 64% |
IQR, interquartile range.
Here defined as CR plus CRi in VIALE-A (pooled analysis) and CR/CRh in AGILE. CR plus CRi in AGILE was 54%.
Data derived from Pollyea et al11 and Montesinos et al.2